سعر فيموجيسال 21 قرص 0.03 مجم / 0.075 مجم 2024

Combined oral contraceptive: ethinylestradiol 0.03 mg + gestodene 0.075 mg film-coated tablets (Technopharma); 21 tablets.

• Oral contraception and the recognised gynaecological indications for such oestrogen-progestogen combinations, considering individual VTE risk factors.Population: Women of reproductive ageemc (medicines.org.uk)

• Most commonly reported (>=1%): nausea, abdominal pain, weight increase, headache, depressed or altered mood, breast pain and tenderness. Serious: arterial and venous thromboembolism.International label, equivalent formulation · emc (medicines.org.uk)

• Presence or risk of venous thromboembolism (current or past VTE, hereditary or acquired predisposition, major surgery with prolonged immobilisation, multiple risk factors) or arterial thromboembolism (past MI/angina, stroke/TIA, migraine with focal neurological symptoms, hereditary predisposition), among other conditions listed in the SmPC.International label, equivalent formulation · emc (medicines.org.uk)

• The decision to prescribe should take into account the woman's current VTE risk factors and how the VTE risk with this gestodene-containing pill compares with other combined hormonal contraceptives.International label, equivalent formulation · emc (medicines.org.uk)
• Irregular bleeding may occur in the first months; persistent irregularities require exclusion of non-hormonal causes, malignancy or pregnancy.International label, equivalent formulation · emc (medicines.org.uk)

• Enzyme inducers (especially CYP3A4 inducers)Increased clearance of sex hormones may cause breakthrough bleeding and contraceptive failure; use a barrier method during and for 28 days after short-term use, or choose another method.emc (medicines.org.uk)

• Not indicated during pregnancy; stop if pregnancy occurs. Extensive epidemiological studies show no increased risk of birth defects from COC use before pregnancy and no teratogenic effect from inadvertent use in early pregnancy.International label, equivalent formulation · emc (medicines.org.uk)
• May reduce milk volume and change its composition; minute amounts pass into milk; another contraceptive method may be advised while breastfeeding.International label, equivalent formulation · emc (medicines.org.uk)

• Ethinylestradiol: With the progestogen, inhibits ovulation by suppressing the mid-cycle LH surge, thickens cervical mucus and makes the endometrium unreceptive to implantation (UK Femodene SmPC 5.1).
• Gestodene: With the estrogen, inhibits ovulation, thickens cervical mucus and renders the endometrium unreceptive (UK Femodene SmPC 5.1).